.png)
.png)
Latest news from BIA
World leading antibody scientist Dr Jane Osbourn awarded OBE in Queen’s Honours
Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca and Chair of the UK BioIndustry Association (BIA) has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.
UK Life Sciences Industry welcomes launch of Health Innovation Research Alliance Northern Ireland
Today, 4 June, sees the unveiling of the UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI) at a BIO reception in Philadelphia hosted by the UK Department for International Trade, Invest Northern Ireland, the Welsh Government, BIA, AstraZeneca and the British American Business Council of Greater Philadelphia. It will be followed by a formal launch event on 5 June at the Union League of Philadelphia from 08:30-10:00 EST.
BIO convention is a global opportunity to champion the UK’s successes says BIA
The UK BioIndustry Association (BIA) will be attending the BIO International Convention 2019, which will be hosted in Philadelphia, USA, from 3 – 6 June.
BIA | New report unveils a thriving service and supply sector for UK medicines discovery
Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness
Oxford Biomedica named as winner of The Oxford Science Park Innovation Award 2019
Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019.
Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK, announce strategic collaboration
Psychiatry Consortium to address unmet patient needs
Bringing the benefits of cutting-edge mass spectrometry technologies to UK SMEs
Medicines Discovery Catapult and Waters partner to support UK medicines discovery with advanced technology solutions.
Why investors trust their gut about the human microbiome
FROM RESULTS HEALTHCARE The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging. While it is in the gut that humans have the most diverse and densely populated microbiota, their influence and presence in other parts of the body has made the microbiome comparable to “a newly discovered organ” and a new route for therapeutic intervention, leading to a wave of start-ups and IPOs in the field.
CEO Update | Monday 17 June
Today, the BIA is pleased to publish a new report, ‘Life sciences: Catalysing investment and growth”. which sets out how our sector is driving investment and growth across the UK and makes the case for increased cost-effective public investment in the sector. The report aims to inform the Government, UKRI and other policy makers as they prepare for the forthcoming Spending Review and develop an R&D roadmap to reach 2.4% R&D target.
Video of the week | How Engineers Move Medicine Around The World
Medicines have complex storage and transportation needs, and getting medicines to remote locations requires lots of planning, clever engineering and infrastructure. Check out this video from SciShow on YouTube to find out more about how medicines are transported around the world.
Labouring the point: How biotech should engage with the Labour Party
There can have been few moments when the political landscape has looked more uncertain, with polls fluctuating wildly, leadership contests in two separate parties and a looming hard deadline for Brexit. But while the machinations of the Conservative Party leadership race rumble on, it is also important not to forget that over on the Opposition benches, new policy is being formed which has a decent chance of being implemented in some form after the next general election. While current opinion polls suggest that the electorate may give many of their votes to the Liberal Democrats or the recently formed Brexit Party, a significant chunk remain with Labour. With Labour’s narrow win in Peterborough by-election fresh in everyone’s minds, it is clear that the party is still in the running.
CEO Update | Tuesday 11 June 2019
Many congratulations to BIA Chair, Dr Jane Osbourn who has been awarded an OBE in the Queen’s birthday honours announced at the weekend. Jane is a true pioneer in our sector, who not only has pioneered world-class research and contributed to blockbuster discoveries but is a passionate advocate for the UK life sciences sector. For me, Jane’s greatest qualities are her abilities to communicate and lead, she has and always will be a trailblazer in our sector and I’m delighted that she has received this award. In Westminster the Conservative leadership contest to replace Theresa May is underway and we have produced a life sciences focused guide to the runners and riders which is available here.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
